BR112014013564A2 - composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz - Google Patents

composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz

Info

Publication number
BR112014013564A2
BR112014013564A2 BR112014013564A BR112014013564A BR112014013564A2 BR 112014013564 A2 BR112014013564 A2 BR 112014013564A2 BR 112014013564 A BR112014013564 A BR 112014013564A BR 112014013564 A BR112014013564 A BR 112014013564A BR 112014013564 A2 BR112014013564 A2 BR 112014013564A2
Authority
BR
Brazil
Prior art keywords
topical pharmaceutical
nose
ear
eye
pharmaceutical compositions
Prior art date
Application number
BR112014013564A
Other languages
English (en)
Other versions
BR112014013564A8 (pt
Inventor
Kumar Dhirendra
Avachat Makrand
Murali Narayanan
K Nagarajan Raja
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112014013564A8 publication Critical patent/BR112014013564A8/pt
Publication of BR112014013564A2 publication Critical patent/BR112014013564A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz a presente invenção proporciona composições farmacêuticas tópicas estáveis durante o armazenamento e estéreis, destinadas à aplicação ao olho, ouvido ou nariz, compreendendo dexametasona e ciprofloxacina. as composições farmacêuticas tópicas da invenção compreendem uma combinação de agente de tonicidade iônico e agente(s) de tonicidade não iônico(s). as composições farmacêuticas tópicas compreendem adicionalmente ácido bórico. a invenção proporciona um processo de preparação e esterilização das composições de modo a reduzir a quantidade de compostos relacionados e impurezas associadas às composições tópicas durante o armazenamento. as composições farmacêuticas tópicas da invenção observadas como sendo estáveis durante o armazenamento são fáceis de ressuspender. 1/1
BR112014013564A 2011-12-09 2012-12-07 composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz BR112014013564A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1534KO2011 2011-12-09
PCT/IB2012/057054 WO2013084194A1 (en) 2011-12-09 2012-12-07 Topical pharmaceutical compositions of anti-microbial agents and anti-inflammatory agents

Publications (2)

Publication Number Publication Date
BR112014013564A8 BR112014013564A8 (pt) 2017-06-13
BR112014013564A2 true BR112014013564A2 (pt) 2017-06-13

Family

ID=48573652

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013564A BR112014013564A2 (pt) 2011-12-09 2012-12-07 composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz

Country Status (4)

Country Link
US (1) US20140315871A1 (pt)
BR (1) BR112014013564A2 (pt)
MX (1) MX2014006803A (pt)
WO (1) WO2013084194A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3006251A1 (en) * 2015-12-07 2017-06-15 Emcure Pharmaceuticals Limited Sterile parenteral suspensions
CN113521001A (zh) * 2020-04-15 2021-10-22 江苏长泰药业有限公司 一种含地塞米松的混悬剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
PT782448E (pt) * 1995-06-06 2002-07-31 Bayer Ag Formulacoes oticas antibacterianas nao ototoxicas nao sensibilizantes nao irritantes
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
TR200200737T2 (tr) * 1999-09-24 2002-08-21 Alcon, Inc. Siproflaksasin ve deksametazon içeren lokal süspansiyon formülasyonları
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
CN1887352A (zh) * 2006-07-13 2007-01-03 徐艳 治疗眼部真菌和细菌感染的组合物
CN101129386A (zh) * 2007-07-17 2008-02-27 长治市三宝生化药业有限公司 一种含环丙沙星和地塞米松的局部悬浮滴眼剂

Also Published As

Publication number Publication date
US20140315871A1 (en) 2014-10-23
BR112014013564A8 (pt) 2017-06-13
MX2014006803A (es) 2014-07-09
WO2013084194A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
CA2863964C (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
MX2015003228A (es) Composiciones de alcanos semifluorados.
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
BR112018013104A2 (pt) composição e método para crescimento de cabelos ou pelos
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
BR112014030820A2 (pt) formulação de anticorpos
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112012030959A2 (pt) emulsões acrílicas intumescíveis em álcali que compreendem ácido acrílico, seu uso em formulações aquosas e formulações que contenham as mesmas
BR112015001313A2 (pt) composições de vacina
BR112016014247A2 (pt) Composição aquosa esterilizada, processos de fabricação da mesma, de obtenção de uma composição aquosa esterilizada de ácido hialurônico, utilizações de mepivacaína, e de uma composição aquosa esterilizada, kit, e, processo para melhorar a resistência à degradação das propriedades reológicas de uma composição aquosa injetável de ácido hialurônico
BR112015002464B8 (pt) processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
BR112014027047A2 (pt) nova formulação
BR112014027582A8 (pt) composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
BR112015015341A2 (pt) composições para permeabilização de células sanguíneas fixadas e usos das mesmas
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112012018154A2 (pt) agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular
BR112015006464A2 (pt) composição farmacêutica compreendendo rebamipida
BR112014013564A2 (pt) composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]